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1. Introduction
Melanoma is a complex disease with both genetic and epigenetic components [1-3]. Once
melanoma has formed distant metastases, melanoma patients have generally poor prognoses;
less than 10% of these patients will survive 10 years [4]. For many years, treatment with the
cytotoxic drug dacarbazine was the standard treatment for patients with metastatic melanoma,
but the response rates were low and varied from 5-20% [4]. Intense research efforts on
understanding the molecular mechanisms of melanoma progression led to the discovery and
the approval by the FDA of two new drugs in 2011, vemurafenib and ipilimumab, which raised
great hopes among melanoma patients [5-12]. Although treatment with vemurafenib has
resulted in high overall responses rates [11], resistance against the drug appeared in treated
melanoma patients within a year of treatment, leading to tumor regrowth [13-16]. On the other
hand, treatment with ipilimumab does not result in resistance but can produce life threatening
autoimmune adverse effects [17]. In addition, ipilimumab works best in patients whose tumors
present abundant tumor infiltrated immune cells [18]. It is therefore essential to identify new
therapeutic targets in melanoma.
One potential therapeutic target is the receptor for advanced glycation end products (RAGE).
A possible role of RAGE in melanoma is emerging and has been the topic of a growing number
of studies in the past decade [19-25]. These studies will be reviewed here and we will also
discuss the RAGE ligands that play important roles in melanoma progression.
2. The Receptor for Advanced Glycation End Products (RAGE)
2.1. RAGE function
RAGE is an immunoglobulin-like cell-surface receptor that is involved in a large number of
pathologies, including Alzheimer’s disease, cancer, infectious diseases and complications of
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diabetes [31-38]. The ligands of RAGE are numerous (Table 1) and belong to distinct families
of molecules. However, they also share structural features such as the propensity to form
oligomers [39]. It is believed that RAGE recognizes similar structural elements or patterns
within its numerous ligands and therefore RAGE is described as a pattern recognition receptor
[40, 41].
Figure 1. Schematic representation of RAGE. The extracellular part of RAGE is composed of three distinct immunoglo‐
bulin-like domains (V, C1 and C2). The V and C1 domains form a structural and functional unit [26]. Most ligands
interact with the V-C1 domain. Four adaptor molecules have been suggested to bind to the intracellular domain of
RAGE: ERK1/2 [27], diaphanous-1 (Dia-1) [28], TIRAP and MyD88 [29]. Following activation of RAGE by its ligands,
multiple signaling pathways (MAPK, PI3K/Akt) or molecules (NADPH oxidase, Rac-1, cdc42) are activated and lead to
the transcription of genes related to inflammation, cell proliferation and migration, and to the expression of RAGE it‐
self, resulting in a positive feedback loop [30].
The physiological role of RAGE is not yet fully understood. Studies have shown that RAGE
plays a role in the innate but not adaptive immunity and has been shown to play an important
function in peripheral nerve repair [42-44]. A characteristic of RAGE is that it is expressed at
low basal level in most tissues except in lungs where it has been suggested to exert a protective
effect [45-48]. RAGE has also been shown to modulate the auditory system in mice [49].
Several spliced isoforms of RAGE have been described. Besides full-length RAGE, presented
in Figure 1, RAGE exists as a soluble form (sRAGE) lacking the intracellular and transmem‐
brane domains. The soluble form can result either from a splicing event or from the action of
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a metalloprotease such as ADAM 10 [50-58]. Other major identified spliced isoforms lack the
N-terminal domain or present a deletion in the intracellular domain, resulting in abnormal
ligand interaction and cell signaling activities, respectively [51, 56, 59]. sRAGE has been used
in many animal experiments to validate the role of RAGE in various diseases such as Alz‐
heimer’s disease, atherosclerosis or encephalomyelitis [60-62]. Two different models explain‐
ing the mechanism of action of sRAGE have been proposed. The “classic” mechanism suggests
that sRAGE acts as a decoy receptor and interacts with circulating RAGE ligands, which results
in the absence of RAGE/ligand complex formation and RAGE activation. Recently, the group
of Fritz has proposed a second mechanism of action for sRAGE: Fritz et al. suggest that sRAGE
could form a complex with the extracellular part of another full-length receptor and that this
receptor complex would not be functional because it possesses only one intracellular domain
[63]. According to this hypothesis, RAGE can only transmit a signal if two intracellular
domains form a dimer [63].
The role of sRAGE as biomarker has also been investigated in many diseases but has resulted
in contradictory data for certain pathologies. In Alzheimer’s disease patients, the circulating
plasma levels of sRAGE have been shown to be significantly reduced compared to healthy
individuals [64]. A more detailed immunohistological examination of AD brain showed that
the reduction in sRAGE was more pronounced in the hippocampus of AD brains than normal
brains [65]. Systemic low levels of sRAGE have also been found in patients with emphysema,
a form of chronic obstructive pulmonary disease (COPD) and sRAGE is suggested to be a
biomarker for this lung disease [66, 67]. However, in diabetes, the situation is more complex
and in different studies the levels of sRAGE have been either positively or negatively correlated
with the disease (reviewed and discussed in [68])
In cancer, an association between sRAGE and the progression of cancer has also been shown.
Significantly lower levels of sRAGE have been found in lung, breast, liver or pancreatic cancer
patients than in normal individuals [69-72]. Our study of 40 melanoma human samples also
showed significantly lower transcript levels of the spliced form of RAGE in 90% of melanoma
stage III and stage IV tissue samples compared to normal samples [73].
2.2. RAGE structure and signaling
RAGE is a single transmembrane receptor with a large extracellular part comprising of three
domains that share structural features with immunoglobulin domains: a variable type (V)
domain (residues 23-119), and two constant type domains (C1: residues 120-233, and C2:
residues 234-325) (Figure 1) [74]. The V and C1 domains form a structural and functional unit
and are the site of binding of most ligands [26].
Recent studies have suggested that RAGE structure is as complex as RAGE signaling is, and
multiple conformational forms of RAGE in complex with its ligands have been proposed [75].
Recent evidence suggests that RAGE exists as a dimer on the surface of cells, in the absence of
ligand [76, 77]. It has been suggested that the interaction of RAGE with its ligands occurs
mainly through electrostatic interactions between the positive charges present on the V and
C1 domains of RAGE and the negative charges present on RAGE ligands [39, 63]. Because both
RAGE and its ligands can form oligomers, several oligomeric models of RAGE in complex
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with its ligands have been proposed to reflect the possible RAGE/ligand interactions [39, 63,
75-79]. RAGE oligomerization could occur through contacts between the V domain [80], C1
domain [80], [77] or C2 domain, [75, 79], in a ligand dependent manner [79].
RAGE signaling is complex and RAGE/ligand interaction results in the activation of multiple
signaling pathways that are ligand and tissue specific (Figure 1) [34, 81-84]. In general, RAGE
engagement by its ligand leads to the activation of key elements of the PI3K/Akt pathways or
the mitogen-activated protein (MAP) kinase signaling pathways which include ERK1/2, p38
and JNK. Small GTPases such as p21-Ras, Rac-1 or cdc42 can also be activated as a result of
RAGE activation [28, 81, 85-87]. In many cases, RAGE activation by its ligands leads to the
initiation of, and sustained inflammation through the activation of the transcription factor NF-
κB, but also AP-1, STAT-3 and CREB (Figure 1) [36-38, 68, 88].
2.3. RAGE in melanoma
A role of RAGE in melanoma progression was first suggested by Huttunen et al [19]. In their
study, the authors generated tumors in mice using the mouse melanoma B16F10 cell-line
expressing either full-length RAGE or a form of RAGE lacking the cytoplasmic domain [19].
Comparison of the number of metastases formed in the two groups of mice revealed that mice
that were implanted with cells expressing the mutant form of RAGE generated significantly
less tumors than mice implanted with cells expressing full-length RAGE. In a different study,
Abe et al. showed that the growth of xenograft tumor in mice could be reduced using anti-
RAGE antibodies [21]. We showed that RAGE overexpression in the WM115 human melanoma
cell line resulted in a significant decrease in cell proliferation, but also in a significant increase
in cell migration and invasion suggesting that RAGE can modulate different aspects of cancer
[24]. We demonstrated that the decrease in cell proliferation was accompanied with a decrease
in the activity of ERK1/2 [24] and p38 (Meghnani et al. 2014, International Journal of Biochem‐
istry and Cell Biology, in press). The recent report of Popa et al. also suggests the presence of
different oligomeric forms of RAGE with different roles and subcellular location during
melanoma progression [25].
Studies in human melanoma tissue samples have shown that RAGE was not present in all
melanoma samples but rather in a subset of samples. Hsieh et al. showed that only 20% tissue
samples showed RAGE staining [20]. Our analysis of 40 samples of human melanoma tissue
samples also showed large variations in RAGE transcripts levels, with up to 50-fold differences
between samples [22].
Other studies have identified RAGE ligands as important elements in melanoma development.
S100B has been studied in details and its role as a diagnostic marker for melanoma patients is
well established (see section 3.1.1 on S100B). Abe et al. showed that AGEs could promote the
proliferation of melanoma cells in culture [21]. Saha et al. showed that S100A8/A9 could attract
B16F10 melanoma cells to a metastatic site, in a RAGE dependent manner [23]. In addition,
our recent study showed a strong correlation between the expression of RAGE and that of its
S100 protein ligands, in mouse xenograft melanoma tumors (Meghnani et al. 2014, Interna‐
tional Journal of Biochemistry and Cell Biology, in press).
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3. RAGE ligands
Since the identification of AGEs as ligands of RAGE, the list of RAGE ligands has grown to
more than ten ligands or groups of ligands (Table 1). In this section, we will discuss the current
knowledge on ligands that have been shown to play a role in melanoma progression, with a
focus on S100 proteins.
RAGE ligand Examples of disease where the ligand is involved References
Advanced glycation end products Inflammation, cancer, Alzheimer’s disease, atherosclerosis,
aging
[74, 89-92]
S100 proteins Inflammation, cancer, aging, neurodegenerative disorders [82, 93-95]
High mobility group box 1 (HMGB-1) Cancer, inflammation, aging [34, 96-99]
Alzheimer’s β-peptide Alzheimer’s disease [32, 60]
Transthyretin Transthyretin amyloidosis [100]
Prion Prion’s disease [101, 102]
Mac-1 Diseases of the immune system [40, 103]
Complement proteins C3a and C1q Diseases of the immune system [104, 105]
Phophatidylserine Diseases of apoptosis [106, 107]
Heparan sulfate Cancer, inflammation, developmental disorder [78, 108, 109]
DNA, RNA Infectious diseases, autoimmune disorders [110]
Table 1. Non-exhaustive list of the different ligands of RAGE. The S100 proteins that are ligands of RAGE will be
described in details in section 3.1
3.1. S100 proteins
Members of the S100 protein family have amino-acid sequence and structure similarities [111,
112]. They are small calcium binding proteins and belong to the superfamily of EF-hand
proteins [111]. Restricted to vertebrates, S100 proteins show strong tissue and cell specificity
[111, 113]. Most S100 genes (S100A1 to S100A16) are located on chromosome 1 in a region that
is prone to chromosomal rearrangement, linking these S100 proteins to cancer [113]. The
presence of EF-hands within the structure of S100 proteins enable them to bind calcium with
moderate micromolar affinity [111, 112, 114, 115]. In addition to calcium, S100 proteins can
also bind zinc and copper [116, 117]. For most S100 proteins, binding to calcium results in
conformational rearrangements that allow the S100 proteins to interact with their targets [115,
117, 118]. Certain target proteins are S100 specific whereas others are shared among multiple
S100s (Reviewed in [119]).
Most S100 target proteins are intracellular [111, 112, 120]. An example of such target that plays
a role in cancer is the tumor suppressor p53 protein [121-126]. Several members of the S100
protein family (S100B, S100A1, S100A2, S100A4, S100A6 and S100A10] bind to p53 but the
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outcome of this interaction differs depending of the S100 [121-126]. S100 proteins can also be
secreted into the extracellular space through mechanisms that are not clearly understood [127,
128]. When secreted, many S100 proteins have been shown to interact with RAGE [82, 93, 129].
Many S100 proteins are found in cells constituting the epidermis [130]. S100B and S100A6 have
been found in both melanocytes and Langerhan’s cells [131-133]. S100A2, A7, A10, A11, A12
and S100A15 have been described in normal keratinocytes [131-138]. In pathophysiological
conditions, such as in inflamed keratinocytes and melanoma, many S100 proteins have been
found overexpressed [130, 136]. The next section will describe the role of these S100 proteins
in melanoma.
3.1.1. S100B
S100B is used as a prognostic marker for stage IV malignant melanoma patients [139-141].
Serum concentration of S100B increases during the disease and high levels of S100B in the
serum is indicative of a poor prognosis [139-141]. In melanoma tumors, melanoma cells are
the main cells responsible for secreting S100B [141]. Within the cells, the role of S100B is not
clearly understood but the main target of S100B appears to be the tumor suppressor p53
protein. Indeed, several studies from the group of Weber have shown that S100B interacts with
p53 in melanoma cells and tumors, resulting in p53 inhibition and increased expression of
S100B, in a negative feedback loop [142-144]. His group is currently investigating small
interfering antisense RNA inhibitors of S100B as inhibitors of melanoma tumor growth [145].
Other intracellular target proteins of S100B could also contribute to increases in cellular
proliferation and tumor growth in melanoma. For example, S100B interacts with and activates
the glycolytic enzyme fructose-1,6-biphosphate aldolase, [146]. Consequences of this activa‐
tion could be an increase in melanoma cell metabolism and glycolysis. Inhibiting melanoma
cell metabolism and glycolysis is currently been considered in clinical trials [147, 148].
Inhibiting S100B/ fructose-1,6-biphosphate aldolase could be an approach to further reduce
glycolytic activity in melanoma cells. S100B also interacts with many components of the
cytoskeleton such as tubulin [149, 150], the actin binding protein caldesmon [151] or the small
GTPase Rac1 and the cdc42 effector IQGAP1 [152]. All these proteins play important function
in malignant melanoma [153-155] and increases in S100B levels could therefore favor increases
in cell proliferation, migration and invasion through their modulation. S100B could also play
a role in melanoma cell growth through the activation of the Nuclear Dbf2 related (ndr) kinase
[156-158] and the interaction with the phosphoprotein AHNAK/desmoyokin [159-161].
As mentioned earlier, S100B is secreted from melanoma cells. The mechanisms of S100B
secretion are still poorly understood but recent studies have suggested that RAGE participates
in the translocation and secretion of several S100s including S100B [127, 128]. Similarly, the
role of RAGE/S100B in melanoma is slowly being unraveled. S100B has been shown to signal
through RAGE in a large number of diseases (reviewed in [162]) and we studied in details the
in vitro interaction of RAGE with S100B [26, 81, 163]. For example, we showed that not only
dimeric S100B but also tetrameric and hexameric S100B could interact with RAGE and signal
in cells [163]. In addition, we recently showed that overexpression of RAGE, in human WM115
melanoma cells, was accompanied by the up-regulation of S100B in these cells [24], suggesting
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a strong association between RAGE and S100B in melanoma. When the RAGE transfected
WM115 cells were implanted in mice as xenografts, we also observed higher levels of S100B
in the serum of these animals, compared to animals implanted with control WM115 cells
(Meghnani et al. 2014, International Journal of Biochemistry and Cell Biology, in press).
3.1.2. S100A2
S100A2 is mainly located in the nuclei of cells [164]. The function of S100A2 in cancer is not
clear. In certain cancers such as prostate, oral, lung and breast cancers, S100A2 has been shown
to play the role of tumor suppressor [22, 165-169], whereas in other cancers such as esophageal
squamous carcinoma, gastric, and ovarian cancer, studies indicate that it acts as tumor
promoter [170-172]. In addition, in certain cancers, such as in non-small cell lung cancer
(NSCLC), studies are contradictory since both down-and up-regulation of S100A2 have been
reported [173-175].
In melanoma, most studies reported that S100A2 plays the role of tumor suppressor [130, 132,
165, 176]. We also showed a significant reduction in S100A2 mRNA level in both stage III and
stage IV melanoma patients samples compared to control samples [22]. Additional evidences
of a tumor suppressor effect of S100A2 comes from several studies that show positive corre‐
lations between the levels of S100A2 and anti-proliferative effects of chemotherapeutic agents
in melanoma cells [177, 178]. However, our most recent study shows that xenograft melanoma
tumors overexpressing RAGE, presented a growth advantage over control tumors, and
exhibited significant higher levels of S100A2 than control tumors (Meghnani et al. 2014,
International Journal of Biochemistry and Cell Biology, in press). We observed that S100A2
was up-regulated, both at the transcript and protein levels, in the RAGE overexpressing tumors
(Meghnani et al. unpublished results). These data suggest a complex role of S100A2 in
promoting or suppressing melanoma tumor growth.
As mentioned above, S100A2 is located in the nuclei of cells and has been shown to interact
with the tumor suppressor p53, in two oral cancer cell lines (FADU and SCC-25), thereby
modulating the transcriptional activity of p53 [123]. In vitro binding studies have confirmed
the interaction between S100A2 and p53 and has shown differences in binding of p53 to S100B
and S100A2; for example, although both S100B and S100A2 could bind to the monomeric form
of p53, only S100B was able to disrupt the oligomerization of p53, suggesting different mode
of transcriptional modulation of p53 by the S100 proteins [124, 126]. In addition to interacting
with p53, S100A2 transcriptional activity is regulated by other members of the large p53 family,
such as p63 and p73, suggesting an additional level of complexity of the S100A2/p53 regulation
[179-181]. In breast cancer tissues and cells, it was shown that both the p53 homologue Np63,
and BRCA1 were important for the transcriptional activity of S100A2 [182]. These recent data
could have a large impact in understanding the molecular mechanism of melanoma because
positive correlations have been found between the BRCA1 associated protein (BAP1] and
malignant uveal and cutaneous melanoma [183-185].
We recently demonstrated that in vitro, S100A2 could interact with RAGE [22] and our recent
study showed an association between RAGE overexpression and the levels of S100A2 in
melanoma xenograft tumors (Meghnani et al. 2014, International Journal of Biochemistry and
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Cell Biology, in press). However, a direct interaction of S100A2/RAGE in melanoma cells and
tissue has yet to be demonstrated.
3.1.3. S100A4
S100A4 was initially identified from metastatic cells and was hence named metastasin [186].
Overexpression of S100A4 in multiple cell lines has been shown to increase cancer cell
invasiveness and motility [187, 188]. The role of S100A4 in cancer was further demonstrated
in S100A4-/-mice that showed delayed tumor growth, compared to control mice, when
implanted with highly metastatic mammary carcinoma cells [189, 190].
In melanoma, the role of S100A4 is complex and appears to vary during the progression of the
disease. An early study showed no significant differences in S100A4 mRNA levels between
melanoma tissue samples and control samples [165]. Our analysis of 40 samples of stage III
and stage IV melanoma tissue samples showed a significantly reduction of S100A4 mRNA in
stage IV compared to control samples [22]. Another study also reported different correlation
between the levels of S100A4 and patient survival rates during the progression of melanoma:
high levels of S100A4 in primary melanoma tumors were associated with low patient survival
rates whereas high S100A4 levels in metastatic tumors were not associated with differences in
patient survival rates, suggesting a role of S100A4 at a early stage of the disease [191].
S100A4 exerts both intra-and extracellular functions (reviewed in [192]).  Inside the cells,
S100A4 can be found in the nuclei and cytoplasm [192]. S100A4 has been shown to interact
with p53 and, as described for S100B, to disrupt p53 oligomerization [193,  194].  In vivo,
interaction of S100A4 with p53 has been shown to promote degradation of p53, resulting
in increases in tumor growth [195]. In the cytoplasm, S100A4 interacts with a large number
of proteins of the cytoskeleton such as non-muscle myosin II [196] and tropomyosin [197],
resulting in cytoskeletal reorganization, which occurs during cell migration and invasion
[198, 199].
An important property of S100A4 is that it has been found secreted in the extracellular medium
of cells and is present in the milieu of many tumor types such as breast cancer [200], ovarian
carcinoma [201], osteosarcoma [202] or adenocarcinoma tumors [203]. Many cells from normal
tissues and from tumors have been shown to release S100A4. These cells include fibroblasts,
leukocytes, and endothelial cells [192, 204]. Extracellular S100A4 has been shown to promote
tumor growth and metastasis [192], neovascularization and angiogenesis [205-207].
Two main targets of extracellular S100A4 with relevance to tumor growth and metastasis have
been identified: Annexin II and RAGE [208, 209]. Interaction of S100A4 with annexin II has
been associated with increased mechanisms of angiogenesis such as the formation of capillary-
like tubes by endothelial cells [208]. S100A4 has been shown to enhance motility of pulmonary
artery smooth muscle cells in a RAGE dependent manner [210]. Similarly, S100A4 was shown
to promote prostate and colorectal cancer tumorigenesis and metastasis in a RAGE dependent
manner [211, 212]. In melanoma, a recent study has demonstrated that S100A4 derived from
macrophages could promote lung colonization of B16F10 melanoma cells in mice, in a RAGE
dependent manner as well [213]. We have also observed that RAGE overexpression in the
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WM115 melanoma cells resulted in the up-regulation of S100A4, by the melanoma cells, in
xenograft tumors implanted in mice (Meghnani et al. 2014, International Journal of Biochem‐
istry and Cell Biology, in press).
3.1.4. S100A6
S100A6 is another member of the S100 family with a link to cancer. S100A6 was identified from
melanoma tissue samples by comparing melanocytic lesions from normal nevi [214]. S100A6
is most abundant in epithelial cells and fibroblasts but is also found, in smaller amounts, in
other cell-types such as neurons, glial cells, smooth muscle cells, cardiac myocytes, platelets
and lymphocytes [215, 216](reviewed in [217]). S100A6 has been found elevated in a large
number of cancer types which include colorectal cancer, pancreatic, hepato-cellular carcinoma,
melanoma, lung cancer and gastric cancer [165, 218-224](reviewed in [217]). In melanoma
tumor samples, a positive correlation was found between the levels of S100A6 transcripts and
the severity of the disease [165]. In animal models, S100A6 was found to correlate with the
metastatic behavior of the melanoma cells [214, 225]. We also observed higher levels of S1006,
at the transcript level, in 43% of stage III melanoma samples examined, compared to control
samples [22]. In agreement with our study, examination of another set of melanoma tissue
samples showed that 33% of the samples stained positive for S100A6 [133]. However, exami‐
nation of melanoma tumor biopsies by immunohistochemistry often shows that the expression
of S100A6 is weak and patchy, and that other non-melanoma cutaneous lesions also stain
positive for S100A6, making it difficult to use S100A6 as a diagnostic marker for melanoma
[176, 226, 227].
S100A6 has been shown to interact with both nuclear and cytoplasmic proteins. S100A6
interacts with the tumor suppressor p53 but this interaction is different than the interaction of
p53 with S100B, suggesting different regulation of the transcriptional activity of p53 by the
two S100 proteins [124, 228]. S100A6 was shown to interact with a peptide derived from cell
membrane associated annexin I, but the physiological relevance of this interaction has yet to
be demonstrated [229]. We showed that S100A6 could interact with both the VC1 and the C2
domain of RAGE, but that in human neuroblastoma, signaling was transduced through the
C2 domain [81]. The interaction of the C3S mutant form of S100A6 with the V domain of RAGE
has recently been studied in details [230]. Similarly to what we observed with S100B, S100A2
and S100A4, RAGE overexpression in the WM115 melanoma cells resulted in the up-regulation
of S100A6, by the melanoma cells, when the cells were forming xenograft tumors in nude mice,
compared to control tumors (Meghnani et al. 2014, International Journal of Biochemistry and
Cell Biology, in press).
3.1.5. S100A8/A9
S100A8 and S100A9 are mainly expressed by cells of myeloid origin such as monocytes and
macrophages, and were first described as cytokine-like proteins for their up-regulation in
inflamed tissues and inflammatory disorders [231]. Recent studies have also shown that they
play significant roles in cancer where they promote tumor growth and metastasis in a large
number of cancers such as in breast, prostate and pancreatic cancer [232-238]. In tumors, recent
studies have shown that S100A8/A9 regulates the accumulation of myeloid-derived suppres‐
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sor cells (MDSC), and also promote the expansion of these cells, resulting in increased tumor
growth [239-243].
Neither S100A8 nor S100A9 is present in significant amounts in the cells of a normal epidermis,
including melanocytes [130, 244]. Although a study described that S100A8/A9 was absent from
melanocytic lesions [244], other studies have suggested that they participate in melanoma
progression. S100A9 has been shown to promote melanoma metastases formation in a mouse
model [245]. In a different mouse model of melanoma, the levels of MDSCs correlated with
the levels of S100A9, [246]. In addition, Saha et al. recently demonstrated that tail-vein injected
B16F10 melanoma cells, that do not express S100A8 or S100A9, could migrate to S100A8/A9-
abondant lungs of uteroglobin-knockout mice [23]. The migration of the B16F10 cells occurred
along a concentration gradient of S100A8/A9, and resulted in the formation of secondary
tumors in the lungs [23].
S100A8/A9 mediates their effect through the interaction with cell surface receptors or mole‐
cules. The two pattern recognition receptors, toll-like receptor 4 (TLR-4) and RAGE, have been
shown to transmit RAGE signaling [23, 247, 248]. In certain conditions, signaling through
RAGE has been shown to require carboxylated glycans that are covalently attached to RAGE
[249, 250]. The importance of RAGE glycosylation for RAGE signaling has also been demon‐
strated for another member of the S100 protein family, S100A12 [251]. S100A8/A9 has been
shown to interact with other glycans, such as heparin or heparin sulfate glycosaminoglycans
[137]. In addition, S100A9 has also been shown to interact with and transmit signal through
EMMPIRIN [245].
3.1.6. Other S100 proteins
Other S100 proteins are found in cells of the epidermis (reviewed by [130]), and their associ‐
ation with melanoma will be briefly described in this paragraph.
S100A7 or “psoriasin” has been linked to psoriasis because of its up-regulation in this disease
[252, 253]. Although no direct role of S100A7 in melanoma has been described yet, in one study,
significantly higher levels of S100A7 were found in the urine of melanoma patients compared
to that of healthy patients [254].
S100A10 has been found expressed at various levels in melanoma tumor samples and mela‐
nocytes [22, 244]. Our recent study where we compared the levels of S100 proteins in WM115
xenografts, generated from either control WM115 cells or from RAGE overexpressing WM115
cells, showed that S100A10 was up-regulated in the RAGE overexpressing tumors (unpub‐
lished data). Comparison of the WM115-RAGE cells with control cells did not reveal any
difference in S100A10 levels between the two cell lines, suggesting that RAGE overexpression
was responsible for the up-regulation of S100A10 in the tumors. S100A10 could therefore play
a role in melanoma progression.
S100A11 can either promote tumor growth or play the role of tumor suppressor, depending
of the type of cancer (reviewed in [255]). S100A11 has been suggested to play a role in uveal
melanoma, but has not yet been linked to cutaneous melanoma [256].
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3.2. Other ligands of RAGE
3.2.1. Advanced Glycation End products (AGEs)
Among RAGE ligands, AGEs were the first group of ligands to be identified [89]. AGEs form
a group of very heterogeneous compounds since they are the result of condensation and
oxidation reactions between proteins and sugars [257]. Although the term AGE was initially
reserved for brown, fluorescent and cross-linked structures that were produced during the
Maillard reaction, such as those found in glycated collagen, it is now used to describe other
types of modifications and AGEs now include proteins containing carboxymethyllysine,
carboxymethyl hydroxylysine or pyrraline [257]. Since many types of sugars (glucose,
ribose…) can modify many proteins, the number of different structures produced by glycation
is very large. The large heterogeneity in AGE compounds renders the comparison among
studies also very difficult. When comparing the results of studies involving AGEs, it is
therefore important to know the type of AGEs used in the study.
Melanoma cells have been shown to produce high levels of reactive carbonyl species such as
glyoxal, methylglyoxal and malondialdehyde, which all can lead to the glycation of proteins,
and which have been implicated in melanoma cell proliferation and formation of metastases
[258-260]. Abe et al. investigated the effects of different AGEs (glucose-derived AGE, glycer‐
aldehyde-derived AGE, glycoaldehyde AGE, methylglyoxal-AGE, glyoxal-AGE and carbox‐
ymethyllysine-AGE) on melanoma cell proliferation, migration and invasion, and showed that
all these AGEs were strongly present in human melanoma specimen whereas they were hardly
detected in melanocytes [21]. However, the same authors showed that only certain types of
AGE compounds (glyceraldehyde-derived AGE and glycoaldehyde AGE) could stimulate the
proliferation, migration and invasion of G361 metastatic human melanoma cells in vitro. The
role of RAGE in the in vitro AGE-dependent proliferation was demonstrated with anti-RAGE
antibodies [21]. In addition, the authors showed that treatment of mice carrying G361 mela‐
noma tumors, with anti-RAGE antibodies, resulted in reduced tumor growth and formation
of lungs metastases [21]. These results strongly suggested a role of AGE/RAGE in the devel‐
opment of melanoma tumors by the G361 human melanoma cell line [21]. Our detailed study
on melanoma cell proliferation of a panel of 20 glycated proteins showed that many factors
influenced the proliferation, such as the extent of lysine modification, the percentage of β-sheet
and the oligomerization state of the glycated proteins [261]. We showed that glycated proteins
that demonstrated higher percentage of oligomeric forms, β-sheet content and modification
of lysine, promoted stronger cell proliferation that proteins that contained lower levels of
oligomers, β-sheet or lysine modification.
3.2.2. High Mobility Group Box 1 protein (HMGB1)
HMGB-1 is present in most eukaryotic cells (reviewed by [97]). It functions both as a nuclear
protein, where it binds to DNA and assists in the transcription of multiple genes, and as an
extracellular protein, where it binds to the pattern recognition receptors TLR-2, TLR-4 and
TLR-9 as well as to RAGE, thereby promoting inflammation, mediating response to infection
and injury as well as promoting cell proliferation, migration or invasion [98, 262-266]. HMGB-1
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is also described as an alarmin or damage-associated molecular pattern [267]. HMGB-1
interacts directly with a large number of transcription factors that are relevant in cancer, and
include the tumor suppressor p53, p73, the retinoblastoma protein (RB), the p50 subunit of
NF-κB and the estrogen receptor (reviewed by [268]). The release of HMGB-1 has been shown
to be triggered by necrosis or apoptosis, such as following treatment of tumors with a chemo‐
therapeutic agent [264, 266, 267].
HMGB-1 has also been shown to be released from necrotic or apoptotic melanoma cells
[269]. A recent study showed that HMGB-1 could be released from keratinocytes in culture,
or  from  murine  skin,  following  exposure  to  UV  light  [270].  Using  a  genetically  engi‐
neered mouse model of melanoma, Bald et al.  showed that UV exposure also promoted
metastasis and angiogenesis,  through HMGB-1, and TLR-4 signaling [271].  In a different
mouse  model,  Tang  et  al.  showed  the  role  of  the  HMGB-1/RAGE  axis  in  promoting
melanoma tumor growth [272]. In melanoma patients, HMGB-1 levels have also been shown
to predict patient survival rates [273].
3.2.3. Glycosaminoglycans, β2 integrin Mac-1 and phosphatidylserine
RAGE has been shown to interact  with various glycosaminoglycans such as chondroitin
sulfate, dermatan sulfate and heparin sulfate [108]. Many of these glycosaminoglycans are
abundantly present in tumor stroma and have been shown to be key players of melano‐
ma progression and metastasis formation [274, 275]. RAGE also interacts with β2 integrin
Mac-1 on leukocytes and has been shown to promote leukocyte recruitment at the site of
inflammation [40].  The interaction between RAGE and Mac-1  is  dependent  of  the  pres‐
ence of cations, and has been shown to be significantly augmented by the presence of S100B.
In a different study, S100A9 has also been shown to activate β2 integrin Mac-1 on neutro‐
phils  suggesting that  other S100 proteins could also participate to the complex between
Mac-1 and RAGE [276]. Leukocyte recruitment at tumor sites is an important process that
allows cytotoxic T-cells to infiltrate tumors and to help in the elimination of cancer cells
[277].  In  melanoma,  success  of  the  therapy  with  interleukin-2  (IL-2)  is  based  on  the
infiltration of cytotoxic T-cells to the interior of the tumor [277]. The involvement of S100
proteins and RAGE in leukocyte recruitment suggests that therapeutic approaches target‐
ing RAGE should be carefully evaluated to avoid inhibiting the recruitment of cytotoxic T-
cells at the site of melanoma tumors. On the other hand, targeting RAGE could also result
in suppressing the recruitment of MDSCs, another form of leukocyte expressing β2 integrin
Mac-1 [278], at the tumor site, which would be beneficial for patients [279, 280].
RAGE has also been shown to interact with the negatively charged phospholipid phosphati‐
dylserine (PS) [106]. This interaction has direct relevance in melanoma because PS has been
shown to be exposed to the outer leaflet of the plasma membrane of cells forming melanoma
metastases [281]. An association between malignancy of melanoma and PS exposure has also
been described [281]. Further studies would be necessary to determine whether RAGE/PS
could be targeted in melanoma.
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4. Conclusion and therapeutic approaches
In the last two decades, RAGE has emerged as a new therapeutic target in a large number of
diseases. Because of the large number of ligands of RAGE that are relevant in melanoma,
targeting RAGE/ligand appears to be a promising approach. Several molecules could be used
as inhibitors and include the soluble form of the receptor (sRAGE), antibodies against RAGE
or small molecules. Both soluble RAGE and anti-RAGE antibodies have been used to demon‐
strate the role of RAGE in experimental models of a large number of diseases such as athero‐
sclerosis, Alzheimer’s disease or melanoma [21, 60, 282-286]. Two small molecule inhibitors of
RAGE are currently available. One compound PFS-ZM1 has been recently used in an experi‐
mental model of Alzheimer’s disease [287]. This inhibitor interacts with the V domain of RAGE
and blocks the interaction of amyloid β-peptide with the receptor. The second compound
(TPP488) has been evaluated for safety and efficacy, in a phase 2 study, in mild to moderate
Alzheimer’s disease patients. However, because of the large variation in the levels of RAGE
observed in melanoma tumor samples, it is currently not known whether targeting RAGE
would be efficacious in all melanoma tumors or only in the subset of tumors where it is
overexpressed. Additional studies would be necessary to answer this important question.
Acknowledgements
The author was supported by the NDSU College of Pharmacy, Nursing and Allied Sciences
and in part by the NDSU Advance FORWARD program sponsored by NSF HRD-0811239 and
ND EPSCoR through grant #EPS-0814442.
Author details
Estelle Leclerc*
Address all correspondence to: Estelle.Leclerc@ndsu.edu
North Dakota State University/Department of Pharmaceutical Sciences, USA
References
[1] Howell PM, Jr., Liu S, Ren S, Behlen C, Fodstad O, Riker AI. Epigenetics in human
melanoma. Cancer Control. 2009;16(3):200-18.
[2] Patino WD, Susa J. Epigenetics of cutaneous melanoma. Adv Dermatol.
2008;24:59-70.
RAGE and Its Ligands in Melanoma
http://dx.doi.org/10.5772/59172
337
[3] Palmieri G, Capone M, Ascierto ML, Gentilcore G, Stroncek DF, Casula M, et al.
Main roads to melanoma. J Transl Med. 2009;7:86.
[4] Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview.
Oncology (Williston Park). 2009;23(6):488-96.
[5] Eggermont AM, Robert C. Melanoma in 2011: A new paradigm tumor for drug de‐
velopment. Nat Rev Clin Oncol. 2012.
[6] Hodi FS, Oble DA, Drappatz J, Velazquez EF, Ramaiya N, Ramakrishna N, et al.
CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female
with melanoma metastases to the CNS. Nat Clin Pract Oncol. 2008;5(9):557-61.
[7] Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal
antibody therapeutics. Nat Rev Drug Discov. 2010;9(10):767-74.
[8] Robert C, Mateus C. [Anti-CTLA-4 monoclonal antibody: a major step in the treat‐
ment of metastatic melanoma]. Med Sci (Paris). 2011;27(10):850-8.
[9] Trinh VA, Hagen B. Ipilimumab for advanced melanoma: A pharmacologic perspec‐
tive. J Oncol Pharm Pract. 2012.
[10] Wang T, Somasundaram R, Herlyn M. Combination therapy of immunocytokines
with ipilimumab: a cure for melanoma? J Invest Dermatol. 2013;133(3):595-6.
[11] Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Im‐
proved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl
J Med. 2011;364(26):2507-16.
[12] Luke JJ, Hodi FS. Vemurafenib and BRAF inhibition: a new class of treatment for
metastatic melanoma. Clin Cancer Res. 2012;18(1):9-14.
[13] Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition
of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):
809-19.
[14] Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire re‐
sistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature.
2010;468(7326):973-7.
[15] Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. Dissecting
therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J
Clin Oncol. 2011;29(22):3085-96.
[16] Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF in‐
hibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
Nature. 2011;480(7377):387-90.
Melanoma – Current Clinical Management and Future Therapeutics338
[17] Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab
monotherapy in patients with pretreated advanced melanoma: a randomised, dou‐
ble-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155-64.
[18] Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and meta‐
stasis. Nat Med. 2013;19(11):1423-37.
[19] Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, Rauvala H. Receptor for advanced
glycation end products-binding COOH-terminal motif of amphoterin inhibits inva‐
sive migration and metastasis. Cancer Res. 2002;62(16):4805-11.
[20] Hsieh HL, Schafer BW, Sasaki N, Heizmann CW. Expression analysis of S100 pro‐
teins and RAGE in human tumors using tissue microarrays. Biochem Biophys Res
Commun. 2003;307(2):375-81.
[21] Abe R, Shimizu T, Sugawara H, Watanabe H, Nakamura H, Choei H, et al. Regula‐
tion of human melanoma growth and metastasis by AGE-AGE receptor interactions.
J Invest Dermatol. 2004;122(2):461-7.
[22] Leclerc E, Heizmann CW, Vetter SW. RAGE and S100 protein transcription levels are
highly variable in human melanoma tumors and cells. Gen Physiol Biophys. 2009;28
Spec No Focus:F65-75.
[23] Saha A, Lee YC, Zhang ZJ, Chandra G, Su SB, Mukherjee AB. Lack of an Endogenous
Anti-inflammatory Protein in Mice Enhances Colonization of B16F10 Melanoma
Cells in the Lungs. Journal of Biological Chemistry. 2010;285(14):10822-31.
[24] Meghnani V, Vetter SW, Leclerc E. RAGE overexpression confers a metastatic pheno‐
type to the WM115 human primary melanoma cell line. Biochim Biophys Acta.
2014;1842(7):1017-27.
[25] Popa I, Ganea E, Petrescu SM. Expression and subcellular localization of RAGE in
melanoma cells. Biochem Cell Biol. 2014;92(2):127-36.
[26] Dattilo BM, Fritz G, Leclerc E, Kooi CW, Heizmann CW, Chazin WJ. The extracellu‐
lar region of the receptor for advanced glycation end products is composed of two
independent structural units. Biochemistry. 2007;46(23):6957-70.
[27] Ishihara K, Tsutsumi K, Kawane S, Nakajima M, Kasaoka T. The receptor for ad‐
vanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like
docking site. FEBS Lett. 2003;550(1-3):107-13.
[28] Hudson BI, Kalea AZ, Del Mar Arriero M, Harja E, Boulanger E, D'Agati V, et al. In‐
teraction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-
stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem.
2008;283(49):34457-68.
RAGE and Its Ligands in Melanoma
http://dx.doi.org/10.5772/59172
339
[29] Sakaguchi M, Murata H, Yamamoto K, Ono T, Sakaguchi Y, Motoyama A, et al. TI‐
RAP, an adaptor protein for TLR2/4, transduces a signal from RAGE phosphorylated
upon ligand binding. PLoS One. 2011;6(8):e23132.
[30] Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a pro‐
gression factor amplifying immune and inflammatory responses. J Clin Invest.
2001;108(7):949-55.
[31] Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced
glycation end products and its ligands. Biochim Biophys Acta. 2000;1498(2-3):99-111.
[32] Yan SD, Bierhaus A, Nawroth PP, Stern DM. RAGE and Alzheimer's disease: a pro‐
gression factor for amyloid-beta-induced cellular perturbation? J Alzheimers Dis.
2009;16(4):833-43.
[33] Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the re‐
ceptor for AGE (RAGE) as common soil in inflammation, immune responses and dia‐
betes mellitus and its complications. Diabetologia. 2009;52(11):2251-63.
[34] Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, et al. RAGE (Receptor
for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and
inflammation. J Transl Med. 2009;7:17.
[35] van Zoelen MA, Achouiti A, van der Poll T. RAGE during infectious diseases. Front
Biosci (Schol Ed). 2011;3:1119-32.
[36] Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in Inflam‐
mation and Cancer. Annual Review of Immunology. 2010;28:367-88.
[37] Ramasamy R, Yan SF, Schmidt AM. Receptor for AGE (RAGE): signaling mecha‐
nisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci.
2011;1243:88-102.
[38] Park S, Yoon SJ, Tae HJ, Shim CY. RAGE and cardiovascular disease. Front Biosci.
2011;16:486-97.
[39] Fritz G. RAGE: a single receptor fits multiple ligands. Trends Biochem Sci.
2011;36(12):625-32.
[40] Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, Linn T, et al. The pattern
recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel
pathway for inflammatory cell recruitment. J Exp Med. 2003;198(10):1507-15.
[41] Lin L. RAGE on the Toll Road? Cellular & molecular immunology. 2006;3(5):351-8.
[42] Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, Hofer S, et al. Receptor
for advanced glycation end products (RAGE) regulates sepsis but not the adaptive
immune response. J Clin Invest. 2004;113(11):1641-50.
Melanoma – Current Clinical Management and Future Therapeutics340
[43] Rong LL, Trojaborg W, Qu W, Kostov K, Yan SD, Gooch C, et al. Antagonism of
RAGE suppresses peripheral nerve regeneration. Faseb J. 2004;18(15):1812-7.
[44] Rong LL, Yan SF, Wendt T, Hans D, Pachydaki S, Bucciarelli LG, et al. RAGE modu‐
lates peripheral nerve regeneration via recruitment of both inflammatory and axonal
outgrowth pathways. Faseb J. 2004;18(15):1818-25.
[45] Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, Pinsky D, et al. Survey of the dis‐
tribution of a newly characterized receptor for advanced glycation end products in
tissues. Am J Pathol. 1993;143(6):1699-712.
[46] Queisser MA, Kouri FM, Konigshoff M, Wygrecka M, Schubert U, Eickelberg O, et al.
Loss of RAGE in pulmonary fibrosis: molecular relations to functional changes in
pulmonary cell types. Am J Respir Cell Mol Biol. 2008;39(3):337-45.
[47] Ramsgaard L, Englert JM, Tobolewski J, Tomai L, Fattman CL, Leme AS, et al. The
role of the receptor for advanced glycation end-products in a murine model of silico‐
sis. PLoS One. 2010;5(3):e9604.
[48] Buckley ST, Ehrhardt C. The receptor for advanced glycation end products (RAGE)
and the lung. J Biomed Biotechnol. 2010:in press.
[49] Sakatani S, Yamada K, Homma C, Munesue S, Yamamoto Y, Yamamoto H, et al. De‐
letion of RAGE causes hyperactivity and increased sensitivity to auditory stimuli in
mice. PLoS One. 2009;4(12):e8309.
[50] Ohe K, Watanabe T, Harada S, Munesue S, Yamamoto Y, Yonekura H, et al. Regula‐
tion of alternative splicing of the receptor for advanced glycation endproducts
(RAGE) through G-rich cis-elements and heterogenous nuclear ribonucleoprotein H.
J Biochem. 2010;147(5):651-9.
[51] Hudson BI, Carter AM, Harja E, Kalea AZ, Arriero M, Yang H, et al. Identification,
classification, and expression of RAGE gene splice variants. Faseb J. 2008;22(5):
1572-80.
[52] Galichet A, Weibel M, Heizmann CW. Calcium-regulated intramembrane proteolysis
of the RAGE receptor. Biochem Biophys Res Commun. 2008;370(1):1-5.
[53] Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, et al. A soluble
form of the receptor for advanced glycation endproducts (RAGE) is produced by
proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and
metalloprotease 10 (ADAM10). Faseb J. 2008;22(10):3716-27.
[54] Zhang L, Bukulin M, Kojro E, Roth A, Metz VV, Fahrenholz F, et al. Receptor for ad‐
vanced glycation end products is subjected to protein ectodomain shedding by met‐
alloproteinases. J Biol Chem. 2008;283(51):35507-16.
[55] Ding Q, Keller JN. Splice variants of the receptor for advanced glycosylation end
products (RAGE) in human brain. Neurosci Lett. 2005;373(1):67-72.
RAGE and Its Ligands in Melanoma
http://dx.doi.org/10.5772/59172
[56] Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, et al. Novel
splice variants of the receptor for advanced glycation end-products expressed in hu‐
man vascular endothelial cells and pericytes, and their putative roles in diabetes-in‐
duced vascular injury. Biochem J. 2003;370(Pt 3):1097-109.
[57] Park IH, Yeon SI, Youn JH, Choi JE, Sasaki N, Choi IH, et al. Expression of a novel
secreted splice variant of the receptor for advanced glycation end products (RAGE)
in human brain astrocytes and peripheral blood mononuclear cells. Mol Immunol.
2004;40(16):1203-11.
[58] Kalea AZ, Reiniger N, Yang H, Arriero M, Schmidt AM, Hudson BI. Alternative
splicing of the murine receptor for advanced glycation end-products (RAGE) gene.
FASEB J. 2009;23(6):1766-74.
[59] Jules J, Maiguel D, Hudson BI. Alternative splicing of the RAGE cytoplasmic domain
regulates cell signaling and function. PLoS One. 2013;8(11):e78267.
[60] Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, et al. RAGE
mediates amyloid-beta peptide transport across the blood-brain barrier and accumu‐
lation in brain. Nat Med. 2003;9(7):907-13.
[61] Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ, Jr., Chow WS, et al. Suppression of accel‐
erated diabetic atherosclerosis by the soluble receptor for advanced glycation end‐
products. Nat Med. 1998;4(9):1025-31.
[62] Yan SS, Wu ZY, Zhang HP, Furtado G, Chen X, Yan SF, et al. Suppression of experi‐
mental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-
cell infiltration of the central nervous system. Nat Med. 2003;9(3):287-93.
[63] Koch M, Chitayat S, Dattilo BM, Schiefner A, Diez J, Chazin WJ, et al. Structural basis
for ligand recognition and activation of RAGE. Structure. 2010;18(10):1342-52.
[64] Emanuele E, D'Angelo A, Tomaino C, Binetti G, Ghidoni R, Politi P, et al. Circulating
levels of soluble receptor for advanced glycation end products in Alzheimer disease
and vascular dementia. Arch Neurol. 2005;62(11):1734-6.
[65] Nozaki I, Watanabe T, Kawaguchi M, Akatsu H, Tsuneyama K, Yamamoto Y, et al.
Reduced expression of endogenous secretory receptor for advanced glycation end‐
products in hippocampal neurons of Alzheimer's disease brains. Arch Histol Cytol.
2007;70(5):279-90.
[66] Cheng DT, Kim DK, Cockayne DA, Belousov A, Bitter H, Cho MH, et al. Systemic
soluble receptor for advanced glycation endproducts is a biomarker of emphysema
and associated with AGER genetic variants in patients with chronic obstructive pul‐
monary disease. Am J Respir Crit Care Med. 2013;188(8):948-57.
[67] Miniati M, Calugi S, Rucci P, Shear MK, Benvenuti A, Santoro D, et al. Predictors of
response among patients with panic disorder treated with medications in a naturalis‐
tic follow-up: the role of adult separation anxiety. J Affect Disord. 2012;136(3):675-9.
Melanoma – Current Clinical Management and Future Therapeutics342
[68] Yan SF, Ramasamy R, Schmidt AM. Soluble RAGE: therapy and biomarker in unrav‐
eling the RAGE axis in chronic disease and aging. Biochem Pharmacol. 2010;79(10):
1379-86.
[69] Jing R, Cui M, Wang J, Wang H. Receptor for advanced glycation end products
(RAGE) soluble form (sRAGE): a new biomarker for lung cancer. Neoplasma.
2010;57(1):55-61.
[70] Tesarova P, Kalousova M, Jachymova M, Mestek O, Petruzelka L, Zima T. Receptor
for advanced glycation end products (RAGE)--soluble form (sRAGE) and gene poly‐
morphisms in patients with breast cancer. Cancer Invest. 2007;25(8):720-5.
[71] Moy KA, Jiao L, Freedman ND, Weinstein SJ, Sinha R, Virtamo J, et al. Soluble recep‐
tor for advanced glycation end products and risk of liver cancer. Hepatology.
2013;57(6):2338-45.
[72] Jiao L, Weinstein SJ, Albanes D, Taylor PR, Graubard BI, Virtamo J, et al. Evidence
that serum levels of the soluble receptor for advanced glycation end products are in‐
versely associated with pancreatic cancer risk: a prospective study. Cancer Res.
2011;71(10):3582-9.
[73] Leclerc E, Heizmann CW, Vetter SW. RAGE and S100 protein transcription levels are
highly variable in human melanoma tumors and cells. General Physiology and Bio‐
physics. 2009;28(Focus Issue):F65-F75.
[74] Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, et al. Cloning and expres‐
sion of a cell surface receptor for advanced glycosylation end products of proteins. J
Biol Chem. 1992;267(21):14998-5004.
[75] Yatime L, Andersen GR. Structural insights into the oligomerization mode of the hu‐
man receptor for advanced glycation end-products. FEBS J. 2013;280(24):6556-68.
[76] Zong H, Madden A, Ward M, Mooney MH, Elliott CT, Stitt AW. Homodimerization
is essential for the receptor for advanced glycation end products (RAGE)-mediated
signal transduction. J Biol Chem. 2010;285(30):23137-46.
[77] Xie J, Reverdatto S, Frolov A, Hoffmann R, Burz DS, Shekhtman A. Structural basis
for pattern recognition by the receptor for advanced glycation end products (RAGE).
J Biol Chem. 2008;283:27255-69.
[78] Xu D, Young JH, Krahn JM, Song D, Corbett KD, Chazin WJ, et al. Stable RAGE-Hep‐
aran Sulfate Complexes Are Essential for Signal Transduction. ACS Chem Biol.
2013;8(7):1611-20.
[79] Wei W, Lampe L, Park S, Vangara BS, Waldo GS, Cabantous S, et al. Disulfide bonds
within the C2 domain of RAGE play key roles in its dimerization and biogenesis.
PLoS One. 2012;7(12):e50736.
RAGE and Its Ligands in Melanoma
http://dx.doi.org/10.5772/59172
343
[80] Xu D, Young J, Song D, Esko JD. Heparan sulfate is essential for high mobility group
protein 1 (HMGB1) signaling by the receptor for advanced glycation end products
(RAGE). J Biol Chem. 2011;286(48):41736-44.
[81] Leclerc E, Fritz G, Weibel M, Heizmann CW, Galichet A. S100B and S100A6 differen‐
tially modulate cell survival by interacting with distinct RAGE (receptor for ad‐
vanced glycation end products) immunoglobulin domains. J Biol Chem. 2007;282(43):
31317-31.
[82] Donato R. RAGE: a single receptor for several ligands and different cellular respons‐
es: the case of certain S100 proteins. Curr Mol Med. 2007;7(8):711-24.
[83] Logsdon CD, Fuentes MK, Huang EH, Arumugam T. RAGE and RAGE ligands in
cancer. Curr Mol Med. 2007;7(8):777-89.
[84] Soman S, Raju R, Sandhya VK, Advani J, Khan AA, Harsha HC, et al. A multicellular
signal transduction network of AGE/RAGE signaling. J Cell Commun Signal.
2013;7(1):19-23.
[85] Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM. Activation of the
receptor for advanced glycation end products triggers a p21(ras)-dependent mito‐
gen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem.
1997;272(28):17810-4.
[86] Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products
(RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cyto‐
plasmic domain of the receptor but different downstream signaling pathways. J Biol
Chem. 1999;274(28):19919-24.
[87] Brozzi F, Arcuri C, Giambanco I, Donato R. S100B Protein Regulates Astrocyte Shape
and Migration via Interaction with Src Kinase: IMPLICATIONS FOR ASTROCYTE
DEVELOPMENT, ACTIVATION, AND TUMOR GROWTH. J Biol Chem.
2009;284(13):8797-811.
[88] Bierhaus A, Stern DM, Nawroth PP. RAGE in inflammation: a new therapeutic tar‐
get? Curr Opin Investig Drugs. 2006;7(11):985-91.
[89] Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, et al. Isolation and charac‐
terization of two binding proteins for advanced glycosylation end products from bo‐
vine lung which are present on the endothelial cell surface. J Biol Chem. 1992;267(21):
14987-97.
[90] Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular
inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc
Res. 2004;63(4):582-92.
[91] Yan SF, Ramasamy R, Schmidt AM. The receptor for advanced glycation endprod‐
ucts (RAGE) and cardiovascular disease. Expert Rev Mol Med. 2009;11:e9.
Melanoma – Current Clinical Management and Future Therapeutics344
[92] Srikanth V, Maczurek A, Phan T, Steele M, Westcott B, Juskiw D, et al. Advanced
glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol
Aging. 2011;32(5):763-77.
[93] Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, et al. RAGE mediates a novel
proinflammatory axis: a central cell surface receptor for S100/calgranulin polypepti‐
des. Cell. 1999;97(7):889-901.
[94] Donato R, Cannon BR, Sorci G, Riuzzi F, Hsu K, Weber DJ, et al. Functions of S100
proteins. Curr Mol Med. 2013;13(1):24-57.
[95] Chen H, Xu C, Jin Q, Liu Z. S100 protein family in human cancer. Am J Cancer Res.
2014;4(2):89-115.
[96] Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, et al. The receptor for advanced
glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation
of neurite outgrowth and co-expression of rage and amphoterin in the developing
nervous system. J Biol Chem. 1995;270(43):25752-61.
[97] Huttunen HJ, Rauvala H. Amphoterin as an extracellular regulator of cell motility:
from discovery to disease. J Intern Med. 2004;255(3):351-66.
[98] Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon
in the immune arsenal. Nat Rev Immunol. 2005;5(4):331-42.
[99] Enokido Y, Yoshitake A, Ito H, Okazawa H. Age-dependent change of HMGB1 and
DNA double-strand break accumulation in mouse brain. Biochem Biophys Res Com‐
mun. 2008;376(1):128-33.
[100] Sousa MM, Yan SD, Stern D, Saraiva MJ. Interaction of the receptor for advanced gly‐
cation end products (RAGE) with transthyretin triggers nuclear transcription factor
kB (NF-kB) activation. Lab Invest. 2000;80(7):1101-10.
[101] Sasaki N, Takeuchi M, Chowei H, Kikuchi S, Hayashi Y, Nakano N, et al. Advanced
glycation end products (AGE) and their receptor (RAGE) in the brain of patients with
Creutzfeldt-Jakob disease with prion plaques. Neurosci Lett. 2002;326(2):117-20.
[102] Natale G, Ferrucci M, Lazzeri G, Paparelli A, Fornai F. Transmission of prions within
the gut and towards the central nervous system. Prion. 2011;5(3):142-9.
[103] Bullard DC, Hu X, Schoeb TR, Axtell RC, Raman C, Barnum SR. Critical requirement
of CD11b (Mac-1) on T cells and accessory cells for development of experimental au‐
toimmune encephalomyelitis. J Immunol. 2005;175(10):6327-33.
[104] Ruan BH, Li X, Winkler AR, Cunningham KM, Kuai J, Greco RM, et al. Complement
C3a, CpG oligos, and DNA/C3a complex stimulate IFN-alpha production in a recep‐
tor for advanced glycation end product-dependent manner. J Immunol. 2010;185(7):
4213-22.
RAGE and Its Ligands in Melanoma
http://dx.doi.org/10.5772/59172
345
[105] Ma W, Rai V, Hudson BI, Song F, Schmidt AM, Barile GR. RAGE binds C1q and en‐
hances C1q-mediated phagocytosis. Cell Immunol. 2012;274(1-2):72-82.
[106] He M, Kubo H, Morimoto K, Fujino N, Suzuki T, Takahasi T, et al. Receptor for ad‐
vanced glycation end products binds to phosphatidylserine and assists in the clear‐
ance of apoptotic cells. EMBO Rep. 2011;12(4):358-64.
[107] Fischer U, Schulze-Osthoff K. New approaches and therapeutics targeting apoptosis
in disease. Pharmacol Rev. 2005;57(2):187-215.
[108] Mizumoto S, Sugahara K. Glycosaminoglycans are functional ligands for receptor for
advanced glycation end-products in tumors. FEBS J. 2013;280(10):2462-70.
[109] Lindahl U, Kjellen L. Pathophysiology of heparan sulphate: many diseases, few
drugs. J Intern Med. 2013;273(6):555-71.
[110] Sirois CM, Jin T, Miller AL, Bertheloot D, Nakamura H, Horvath GL, et al. RAGE is a
nucleic acid receptor that promotes inflammatory responses to DNA. J Exp Med.
2013;210(11):2447-63.
[111] Heizmann CW, Fritz G, Schäfer BW. S100 proteins: structure, functions and patholo‐
gy. Front Biosci. 2002;7:d1356-68.
[112] Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech.
2003;60(6):540-51.
[113] Marenholz I, Lovering RC, Heizmann CW. An update of the S100 nomenclature. Bio‐
chim Biophys Acta. 2006;1763(11):1282-3.
[114] Heizmann CW, Ackermann GE, Galichet A. Pathologies involving the S100 proteins
and RAGE. Subcell Biochem. 2007;45:93-138.
[115] Zimmer DB, Weber DJ. The Calcium-Dependent Interaction of S100B with Its Protein
Targets. Cardiovasc Psychiatry Neurol. 2010;2010.
[116] Moroz OV, Wilson KS, Bronstein IB. The role of zinc in the S100 proteins: insights
from the X-ray structures. Amino Acids 2010:in press.
[117] Fritz G, Heizmann CW. 3D Structures of the Calcium and Zinc Binding S100 Pro‐
teins. In: Sons JW, editor. Encyclopedia of Inorganic and Bioinorganic Chemistry: Wi‐
ley Online Library; 2011.
[118] Nelson MR, Thulin E, Fagan PA, Forsen S, Chazin WJ. The EF-hand domain: a glob‐
ally cooperative structural unit. Protein Sci. 2002;11(2):198-205.
[119] Leclerc E, Heizmann CW. The importance of Ca2+/Zn2+signaling S100 proteins and
RAGE in translational medicine. Frontiers in Biosciences. 2011;S3:1232-62.
[120] Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS. Calcium-dependent and-inde‐
pendent interactions of the S100 protein family. Biochem J. 2006;396(2):201-14.
Melanoma – Current Clinical Management and Future Therapeutics346
[121] Baudier J, Delphin C, Grunwald D, Khochbin S, Lawrence JJ. Characterization of the
tumor suppressor protein p53 as a protein kinase C substrate and a S100b-binding
protein. Proc Natl Acad Sci U S A. 1992;89(23):11627-31.
[122] Wilder PT, Lin J, Bair CL, Charpentier TH, Yang D, Liriano M, et al. Recognition of
the tumor suppressor protein p53 and other protein targets by the calcium-binding
protein S100B. Biochim Biophys Acta. 2006;1763(11):1284-97.
[123] Mueller A, Schäfer BW, Ferrari S, Weibel M, Makek M, Hochli M, et al. The calcium-
binding protein S100A2 interacts with p53 and modulates its transcriptional activity.
J Biol Chem. 2005;280(32):29186-93.
[124] Fernandez-Fernandez MR, Rutherford TJ, Fersht AR. Members of the S100 family
bind p53 in two distinct ways. Protein Sci. 2008;17(10):1663-70.
[125] van Dieck J, Teufel DP, Jaulent AM, Fernandez-Fernandez MR, Rutherford TJ, Wy‐
slouch-Cieszynska A, et al. Posttranslational modifications affect the interaction of
S100 proteins with tumor suppressor p53. J Mol Biol. 2009;394(5):922-30.
[126] van Dieck J, Fernandez-Fernandez MR, Veprintsev DB, Fersht AR. Modulation of the
oligomerization state of p53 by differential binding of proteins of the S100 family to
p53 monomers and tetramers. J Biol Chem. 2009;284(20):13804-11.
[127] Hsieh HL, Schäfer BW, Weigle B, Heizmann CW. S100 protein translocation in re‐
sponse to extracellular S100 is mediated by receptor for advanced glycation endprod‐
ucts in human endothelial cells. Biochem Biophys Res Commun. 2004;316(3):949-59.
[128] Perrone L, Peluso G, Melone MA. RAGE recycles at the plasma membrane in S100B
secretory vesicles and promotes Schwann cells morphological changes. J Cell Physi‐
ol. 2008;217(1):60-71.
[129] Leclerc E, Fritz G, Vetter SW, Heizmann CW. Binding of S100 proteins to RAGE: an
update. Biochim Biophys Acta. 2009;1793(6):993-1007.
[130] Eckert RL, Broome AM, Ruse M, Robinson N, Ryan D, Lee K. S100 proteins in the
epidermis. Journal of Investigative Dermatology. 2004;123(1):23-33.
[131] Ito M, Kizawa K. Expression of calcium-binding S100 proteins A4 and A6 in regions
of the epithelial sac associated with the onset of hair follicle regeneration. J Invest
Dermatol. 2001;116(6):956-63.
[132] Boni R, Burg G, Doguoglu A, Ilg EC, Schafer BW, Muller B, et al. Immunohistochemi‐
cal localization of the Ca2+binding S100 proteins in normal human skin and melano‐
cytic lesions. Br J Dermatol. 1997;137(1):39-43.
[133] Ribe A, McNutt NS. S100A6 protein expression is different in Spitz nevi and melano‐
mas. Mod Pathol. 2003;16(5):505-11.
RAGE and Its Ligands in Melanoma
http://dx.doi.org/10.5772/59172
347
[134] Zhang T, Woods TL, Elder JT. Differential responses of S100A2 to oxidative stress
and increased intracellular calcium in normal, immortalized, and malignant human
keratinocytes. J Invest Dermatol. 2002;119(5):1196-201.
[135] Deshpande R, Woods TL, Fu J, Zhang T, Stoll SW, Elder JT. Biochemical characteriza‐
tion of S100A2 in human keratinocytes: subcellular localization, dimerization, and
oxidative cross-linking. J Invest Dermatol. 2000;115(3):477-85.
[136] Broome AM, Ryan D, Eckert RL. S100 protein subcellular localization during epider‐
mal differentiation and psoriasis. Journal of Histochemistry & Cytochemistry.
2003;51(5):675-85.
[137] Robinson MJ, Tessier P, Poulsom R, Hogg N. The S100 family heterodimer,
MRP-8/14, binds with high affinity to heparin and heparan sulfate glycosaminogly‐
cans on endothelial cells. J Biol Chem. 2002;277(5):3658-65.
[138] Mirmohammadsadegh A, Tschakarjan E, Ljoljic A, Bohner K, Michel G, Ruzicka T, et
al. Calgranulin C is overexpressed in lesional psoriasis. Journal of Investigative Der‐
matology. 2000;114(6):1207-8.
[139] Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final
version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):
6199-206.
[140] Ghanem G, Loir B, Morandini R, Sales F, Lienard D, Eggermont A, et al. On the re‐
lease and half-life of S100B protein in the peripheral blood of melanoma patients. Int
J Cancer. 2001;94(4):586-90.
[141] Harpio R, Einarsson R. S100 proteins as cancer biomarkers with focus on S100B in
malignant melanoma. Clin Biochem. 2004;37(7):512-8.
[142] Lin J, Blake M, Tang C, Zimmer D, Rustandi RR, Weber DJ, et al. Inhibition of p53
transcriptional activity by the S100B calcium-binding protein. J Biol Chem.
2001;276(37):35037-41.
[143] Lin J, Yang Q, Wilder PT, Carrier F, Weber DJ. The calcium-binding protein S100B
down-regulates p53 and apoptosis in malignant melanoma. J Biol Chem.
2010;285(35):27487-98.
[144] Lin J, Yang Q, Yan Z, Markowitz J, Wilder PT, Carrier F, et al. Inhibiting S100B re‐
stores p53 levels in primary malignant melanoma cancer cells. J Biol Chem.
2004;279(32):34071-7.
[145] Cavalier M, Wilder PT, Coop A, MacKerell A, Weber DJ, editors. Inhibitors of S100B
(SBiXs) in malignant melanoma. AACR-NCI-EORTC International Conference: Mo‐
lecular Targets and Cancer Therapeutics; 2013; Boston, MA: Mol Cancer Ther.
Melanoma – Current Clinical Management and Future Therapeutics348
[146] Zimmer DB, Van Eldik LJ. Identification of a molecular target for the calcium-modu‐
lated protein S100. Fructose-1,6-bisphosphate aldolase. J Biol Chem. 1986;261(24):
11424-8.
[147] Hersey P, Watts RN, Zhang XD, Hackett J. Metabolic approaches to treatment of mel‐
anoma. Clin Cancer Res. 2009;15(21):6490-4.
[148] Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, et al. Inhibition of glycoly‐
sis in cancer cells: a novel strategy to overcome drug resistance associated with mito‐
chondrial respiratory defect and hypoxia. Cancer Res. 2005;65(2):613-21.
[149] Donato R. Calcium-independent, pH-regulated effects of S-100 proteins on assembly-
disassembly of brain microtubule protein in vitro. J Biol Chem. 1988;263(1):106-10.
[150] Ferguson PL, Shaw GS. Human S100B protein interacts with the Escherichia coli divi‐
sion protein FtsZ in a calcium-sensitive manner. J Biol Chem. 2004;279(18):18806-13.
[151] Skripnikova EV, Gusev NB. Interaction of smooth muscle caldesmon with S-100 pro‐
tein. FEBS Lett. 1989;257(2):380-2.
[152] Mbele GO, Deloulme JC, Gentil BJ, Delphin C, Ferro M, Garin J, et al. The zinc-and
calcium-binding S100B interacts and co-localizes with IQGAP1 during dynamic rear‐
rangement of cell membranes. J Biol Chem. 2002;277(51):49998-50007.
[153] Koganehira Y, Takeoka M, Ehara T, Sasaki K, Murata H, Saida T, et al. Reduced ex‐
pression of actin-binding proteins, h-caldesmon and calponin h1, in the vascular
smooth muscle inside melanoma lesions: an adverse prognostic factor for malignant
melanoma. Br J Dermatol. 2003;148(5):971-80.
[154] Wang Z, Chen J, Wang J, Ahn S, Li CM, Lu Y, et al. Novel tubulin polymerization
inhibitors overcome multidrug resistance and reduce melanoma lung metastasis.
Pharm Res. 2012;29(11):3040-52.
[155] Jameson KL, Mazur PK, Zehnder AM, Zhang J, Zarnegar B, Sage J, et al. IQGAP1
scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tu‐
mors. Nat Med. 2013;19(5):626-30.
[156] Bhattacharya S, Large E, Heizmann CW, Hemmings B, Chazin WJ. Structure of the
Ca2+/S100B/NDR kinase peptide complex: insights into S100 target specificity and
activation of the kinase. Biochemistry. 2003;42(49):14416-26.
[157] Bichsel SJ, Tamaskovic R, Stegert MR, Hemmings BA. Mechanism of activation of
NDR (nuclear Dbf2-related) protein kinase by the hMOB1 protein. J Biol Chem.
2004;279(34):35228-35.
[158] Millward TA, Heizmann CW, Schafer BW, Hemmings BA. Calcium regulation of
Ndr protein kinase mediated by S100 calcium-binding proteins. Embo J. 1998;17(20):
5913-22.
[159] Gentil BJ, Delphin C, Mbele GO, Deloulme JC, Ferro M, Garin J, et al. The giant pro‐
tein AHNAK is a specific target for the calcium-and zinc-binding S100B protein: po‐
RAGE and Its Ligands in Melanoma
http://dx.doi.org/10.5772/59172
349
tential implications for Ca2+homeostasis regulation by S100B. J Biol Chem.
2001;276(26):23253-61.
[160] Shtivelman E, Bishop JM. The human gene AHNAK encodes a large phosphoprotein
located primarily in the nucleus. J Cell Biol. 1993;120(3):625-30.
[161] Fedida-Metula S, Elhyany S, Tsory S, Segal S, Hershfinkel M, Sekler I, et al. Targeting
lipid rafts inhibits protein kinase B by disrupting calcium homeostasis and attenuates
malignant properties of melanoma cells. Carcinogenesis. 2008;29(8):1546-54.
[162] Donato R, Sorci G, Riuzzi F, Arcuri C, Bianchi R, Brozzi F, et al. S100B's double life:
intracellular regulator and extracellular signal. Biochim Biophys Acta. 2009;1793(6):
1008-22.
[163] Ostendorp T, Leclerc E, Galichet A, Koch M, Demling N, Weigle B, et al. Structural
and functional insights into RAGE activation by multimeric S100B. Embo J.
2007;26(16):3868-78.
[164] Glenney JR, Jr., Kindy MS, Zokas L. Isolation of a new member of the S100 protein
family: amino acid sequence, tissue, and subcellular distribution. J Cell Biol.
1989;108(2):569-78.
[165] Maelandsmo GM, Florenes VA, Mellingsaeter T, Hovig E, Kerbel RS, Fodstad O. Dif‐
ferential expression patterns of S100A2, S100A4 and S100A6 during progression of
human malignant melanoma. Int J Cancer. 1997;74(4):464-9.
[166] Gupta S, Hussain T, MacLennan GT, Fu P, Patel J, Mukhtar H. Differential expres‐
sion of S100A2 and S100A4 during progression of human prostate adenocarcinoma. J
Clin Oncol. 2003;21(1):106-12.
[167] Suzuki F, Oridate N, Homma A, Nakamaru Y, Nagahashi T, Yagi K, et al. S100A2 ex‐
pression as a predictive marker for late cervical metastasis in stage I and II invasive
squamous cell carcinoma of the oral cavity. Oncol Rep. 2005;14(6):1493-8.
[168] Feng G, Xu X, Youssef EM, Lotan R. Diminished expression of S100A2, a putative tu‐
mor suppressor, at early stage of human lung carcinogenesis. Cancer Res.
2001;61(21):7999-8004.
[169] Lee SW, Tomasetto C, Swisshelm K, Keyomarsi K, Sager R. Down-regulation of a
member of the S100 gene family in mammary carcinoma cells and reexpression by
azadeoxycytidine treatment. Proc Natl Acad Sci U S A. 1992;89(6):2504-8.
[170] Imazawa M, Hibi K, Fujitake S, Kodera Y, Ito K, Akiyama S, et al. S100A2 overex‐
pression is frequently observed in esophageal squamous cell carcinoma. Anticancer
Res. 2005;25:1247-50.
[171] El-Rifai W, Moskaluk CA, Abdrabbo MK, Harper J, Yoshida C, Riggins GJ, et al. Gas‐
tric cancers overexpress S100A calcium-binding proteins. Cancer Res. 2002;62(23):
6823-6.
Melanoma – Current Clinical Management and Future Therapeutics350
[172] Hough CD, Cho KR, Zonderman AB, Schwartz DR, Morin PJ. Coordinately up-regu‐
lated genes in ovarian cancer. Cancer Res. 2001;61(10):3869-76.
[173] Smith SL, Gugger M, Hoban P, Ratschiller D, Watson SG, Field JK, et al. S100A2 is
strongly expressed in airway basal cells, preneoplastic bronchial lesions and primary
non-small cell lung carcinomas. Br J Cancer. 2004;91(8):1515-24.
[174] Strazisar M, Mlakar V, Glavac D. The expression of COX-2, hTERT, MDM2, LATS2
and S100A2 in different types of non-small cell lung cancer (NSCLC). Cell Mol Biol
Lett. 2009;14(3):442-56.
[175] Bulk E, Sargin B, Krug U, Hascher A, Jun Y, Knop M, et al. S100A2 induces metasta‐
sis in non-small cell lung cancer. Clin Cancer Res. 2009;15(1):22-9.
[176] Nonaka D, Chiriboga L, Rubin BP. Differential expression of S100 protein subtypes
in malignant melanoma, and benign and malignant peripheral nerve sheath tumors.
J Cutan Pathol. 2008;35(11):1014-9.
[177] Gollob JA, Sciambi CJ. Decitabine up-regulates S100A2 expression and synergizes
with IFN-gamma to kill uveal melanoma cells. Clin Cancer Res. 2007;13(17):5219-25.
[178] Klopper JP, Sharma V, Bissonnette R, Haugen BR. Combination PPARgamma and
RXR Agonist Treatment in Melanoma Cells: Functional Importance of S100A2. PPAR
Res. 2010;2010:729876.
[179] Tan M, Heizmann CW, Guan K, Schafer BW, Sun Y. Transcriptional activation of the
human S100A2 promoter by wild-type p53. FEBS Lett. 1999;445(2-3):265-8.
[180] Lapi E, Iovino A, Fontemaggi G, Soliera AR, Iacovelli S, Sacchi A, et al. S100A2 gene
is a direct transcriptional target of p53 homologues during keratinocyte differentia‐
tion. Oncogene. 2006;25(26):3628-37.
[181] Kirschner RD, Sanger K, Muller GA, Engeland K. Transcriptional activation of the tu‐
mor suppressor and differentiation gene S100A2 by a novel p63-binding site. Nucleic
Acids Res. 2008;36(9):2969-80.
[182] Buckley NE, D'Costa Z, Kaminska M, Mullan PB. S100A2 is a BRCA1/p63 coregulat‐
ed tumour suppressor gene with roles in the regulation of mutant p53 stability. Cell
death & disease. 2014;5:e1070.
[183] Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al. Frequent
mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330(6009):1410-3.
[184] Carbone M, Ferris LK, Baumann F, Napolitano A, Lum CA, Flores EG, et al. BAP1
cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and
MBAITs. J Transl Med. 2012;10:179.
[185] Njauw CN, Kim I, Piris A, Gabree M, Taylor M, Lane AM, et al. Germline BAP1 inac‐
tivation is preferentially associated with metastatic ocular melanoma and cutaneous-
ocular melanoma families. PLoS One. 2012;7(4):e35295.
RAGE and Its Ligands in Melanoma
http://dx.doi.org/10.5772/59172
351
[186] Ebralidze A, Tulchinsky E, Grigorian M, Afanasyeva A, Senin V, Revazova E, et al.
Isolation and characterization of a gene specifically expressed in different metastatic
cells and whose deduced gene product has a high degree of homology to a Ca2+-bind‐
ing protein family. Genes Dev. 1989;3(7):1086-93.
[187] Takenaga K, Nakamura Y, Endo H, Sakiyama S. Involvement of S100-related calci‐
um-binding protein pEL98 (or mts1) in cell motility and tumor cell invasion. Japa‐
nese journal of cancer research : Gann. 1994;85(8):831-9.
[188] Jenkinson SR, Barraclough R, West CR, Rudland PS. S100A4 regulates cell motility
and invasion in an in vitro model for breast cancer metastasis. Br J Cancer. 2004;90(1):
253-62.
[189] Grum-Schwensen B, Klingelhofer J, Berg CH, El-Naaman C, Grigorian M, Lukanidin
E, et al. Suppression of tumor development and metastasis formation in mice lacking
the S100A4(mts1) gene. Cancer Res. 2005;65(9):3772-80.
[190] Ambartsumian N, Grigorian M, Lukanidin E. Genetically modified mouse models to
study the role of metastasis-promoting S100A4(mts1) protein in metastatic mammary
cancer. J Dairy Res. 2005;72 Spec No:27-33.
[191] Andersen K, Nesland JM, Holm R, Florenes VA, Fodstad O, Maelandsmo GM. Ex‐
pression of S100A4 combined with reduced E-cadherin expression predicts patient
outcome in malignant melanoma. Mod Pathol. 2004;17(8):990-7.
[192] Boye K, Maelandsmo GM. S100A4 and metastasis: a small actor playing many roles.
Am J Pathol. 2010;176(2):528-35.
[193] Fernandez-Fernandez MR, Veprintsev DB, Fersht AR. Proteins of the S100 family
regulate the oligomerization of p53 tumor suppressor. Proc Natl Acad Sci U S A.
2005;102(13):4735-40.
[194] Berge G, Maelandsmo GM. Evaluation of potential interactions between the metasta‐
sis-associated protein S100A4 and the tumor suppressor protein p53. Amino Acids.
2010:in press.
[195] Orre LM, Panizza E, Kaminskyy VO, Vernet E, Graslund T, Zhivotovsky B, et al.
S100A4 interacts with p53 in the nucleus and promotes p53 degradation. Oncogene.
2013;32(49):5531-40.
[196] Ford HL, Zain SB. Interaction of metastasis associated Mts1 protein with nonmuscle
myosin. Oncogene. 1995;10(8):1597-605.
[197] Takenaga K, Nakamura Y, Sakiyama S, Hasegawa Y, Sato K, Endo H. Binding of
pEL98 protein, an S100-related calcium-binding protein, to nonmuscle tropomyosin.
J Cell Biol. 1994;124(5):757-68.
[198] Li ZH, Bresnick AR. The S100A4 metastasis factor regulates cellular motility via a di‐
rect interaction with myosin-IIA. Cancer Res. 2006;66(10):5173-80.
Melanoma – Current Clinical Management and Future Therapeutics352
[199] Kriajevska M, Bronstein IB, Scott DJ, Tarabykina S, Fischer-Larsen M, Issinger O, et
al. Metastasis-associated protein Mts1 (S100A4) inhibits CK2-mediated phosphoryla‐
tion and self-assembly of the heavy chain of nonmuscle myosin. Biochim Biophys
Acta. 2000;1498(2-3):252-63.
[200] Cabezon T, Celis JE, Skibshoj I, Klingelhofer J, Grigorian M, Gromov P, et al. Expres‐
sion of S100A4 by a variety of cell types present in the tumor microenvironment of
human breast cancer. Int J Cancer. 2007;121(7):1433-44.
[201] Kikuchi N, Horiuchi A, Osada R, Imai T, Wang C, Chen X, et al. Nuclear expression
of S100A4 is associated with aggressive behavior of epithelial ovarian carcinoma: an
important autocrine/paracrine factor in tumor progression. Cancer Sci. 2006;97(10):
1061-9.
[202] Pedersen KB, Andersen K, Fodstad O, Maelandsmo GM. Sensitization of interferon-
gamma induced apoptosis in human osteosarcoma cells by extracellular S100A4.
BMC Cancer. 2004;4:52.
[203] Schmidt-Hansen B, Klingelhofer J, Grum-Schwensen B, Christensen A, Andresen S,
Kruse C, et al. Functional significance of metastasis-inducing S100A4(Mts1) in tumor-
stroma interplay. J Biol Chem. 2004;279(23):24498-504.
[204] Gibbs FE, Barraclough R, Platt-Higgins A, Rudland PS, Wilkinson MC, Parry EW.
Immunocytochemical distribution of the calcium-binding protein p9Ka in normal rat
tissues: variation in the cellular location in different tissues. J Histochem Cytochem.
1995;43(2):169-80.
[205] Ambartsumian N, Klingelhofer J, Grigorian M, Christensen C, Kriajevska M, Tul‐
chinsky E, et al. The metastasis-associated Mts1(S100A4) protein could act as an an‐
giogenic factor. Oncogene. 2001;20(34):4685-95.
[206] Ochiya T, Takenaga K, Endo H. Silencing of S100A4, a metastasis-associated protein,
in endothelial cells inhibits tumor angiogenesis and growth. Angiogenesis.
2014;17(1):17-26.
[207] Schmidt-Hansen B, Ornas D, Grigorian M, Klingelhofer J, Tulchinsky E, Lukanidin E,
et al. Extracellular S100A4(mts1) stimulates invasive growth of mouse endothelial
cells and modulates MMP-13 matrix metalloproteinase activity. Oncogene.
2004;23(32):5487-95.
[208] Semov A, Moreno MJ, Onichtchenko A, Abulrob A, Ball M, Ekiel I, et al. Metastasis-
associated protein S100A4 induces angiogenesis through interaction with Annexin II
and accelerated plasmin formation. J Biol Chem. 2005;280(21):20833-41.
[209] Kiryushko D, Novitskaya V, Soroka V, Klingelhofer J, Lukanidin E, Berezin V, et al.
Molecular mechanisms of Ca2+signaling in neurons induced by the S100A4 protein.
Mol Cell Biol. 2006;26(9):3625-38.
[210] Spiekerkoetter E, Guignabert C, de Jesus Perez V, Alastalo TP, Powers JM, Wang L,
et al. S100A4 and bone morphogenetic protein-2 codependently induce vascular
RAGE and Its Ligands in Melanoma
http://dx.doi.org/10.5772/59172
353
smooth muscle cell migration via phospho-extracellular signal-regulated kinase and
chloride intracellular channel 4. Circ Res. 2009;105(7):639-47, 13 p following 47.
[211] Dahlmann M, Okhrimenko A, Marcinkowski P, Osterland M, Herrmann P, Smith J,
et al. RAGE mediates S100A4-induced cell motility via MAPK/ERK and hypoxia sig‐
naling and is a prognostic biomarker for human colorectal cancer metastasis. Onco‐
target. 2014;5(10):3220-33.
[212] Siddique HR, Adhami VM, Parray A, Johnson JJ, Siddiqui IA, Shekhani MT, et al.
The S100A4 Oncoprotein Promotes Prostate Tumorigenesis in a Transgenic Mouse
Model: Regulating NFkappaB through the RAGE Receptor. Genes & cancer.
2013;4(5-6):224-34.
[213] Haase-Kohn C, Wolf S, Herwig N, Mosch B, Pietzsch J. Metastatic potential of B16-
F10 melanoma cells is enhanced by extracellular S100A4 derived from RAW264.7
macrophages. Biochem Biophys Res Commun. 2014;446(1):143-8.
[214] Weterman MA, van Muijen GN, Bloemers HP, Ruiter DJ. Expression of calcyclin in
human melanocytic lesions. Cancer Res. 1993;53(24):6061-6.
[215] Kuznicki J, Kordowska J, Puzianowska M, Wozniewicz BM. Calcyclin as a marker of
human epithelial cells and fibroblasts. Exp Cell Res. 1992;200(2):425-30.
[216] Kuznicki J, Filipek A, Heimann P, Kaczmarek L, Kaminska B. Tissue specific distri‐
bution of calcyclin--10.5 kDa Ca2+-binding protein. FEBS Lett. 1989;254(1-2):141-4.
[217] Lesniak W, Slomnicki LP, Filipek A. S100A6-new facts and features. Biochem Bio‐
phys Res Commun. 2009;390(4):1087-92.
[218] Komatsu K, Andoh A, Ishiguro S, Suzuki N, Hunai H, Kobune-Fujiwara Y, et al. In‐
creased expression of S100A6 (Calcyclin), a calcium-binding protein of the S100 fami‐
ly, in human colorectal adenocarcinomas. Clin Cancer Res. 2000;6(1):172-7.
[219] Nedjadi T, Kitteringham N, Campbell F, Jenkins RE, Park BK, Navarro P, et al.
S100A6 binds to annexin 2 in pancreatic cancer cells and promotes pancreatic cancer
cell motility. Br J Cancer. 2009;101(7):1145-54.
[220] De Petris L, Orre LM, Kanter L, Pernemalm M, Koyi H, Lewensohn R, et al. Tumor
expression of S100A6 correlates with survival of patients with stage I non-small-cell
lung cancer. Lung Cancer. 2009;63:410-7.
[221] Ohuchida K, Mizumoto K, Yu J, Yamaguchi H, Konomi H, Nagai E, et al. S100A6 is
increased in a stepwise manner during pancreatic carcinogenesis: clinical value of ex‐
pression analysis in 98 pancreatic juice samples. Cancer Epidemiol Biomarkers Prev.
2007;16(4):649-54.
[222] Yang YQ, Zhang LJ, Dong H, Jiang CL, Zhu ZG, Wu JX, et al. Upregulated expres‐
sion of S100A6 in human gastric cancer. J Dig Dis. 2007;8(4):186-93.
Melanoma – Current Clinical Management and Future Therapeutics354
[223] Vimalachandran D, Greenhalf W, Thompson C, Luttges J, Prime W, Campbell F, et
al. High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in
pancreatic cancer patients. Cancer Res. 2005;65(8):3218-25.
[224] Li Z, Tang M, Ling B, Liu S, Zheng Y, Nie C, et al. Increased expression of S100A6
promotes cell proliferation and migration in human hepatocellular carcinoma. Jour‐
nal of molecular medicine. 2014;92(3):291-303.
[225] Weterman MA, Stoopen GM, van Muijen GN, Kuznicki J, Ruiter DJ, Bloemers HP.
Expression of calcyclin in human melanoma cell lines correlates with metastatic be‐
havior in nude mice. Cancer Res. 1992;52(5):1291-6.
[226] Fullen DR, Garrisi AJ, Sanders D, Thomas D. Expression of S100A6 protein in a
broad spectrum of cutaneous tumors using tissue microarrays. J Cutan Pathol.
2008;35 Suppl 2:28-34.
[227] Puri PK, Elston CA, Tyler WB, Ferringer TC, Elston DM. The staining pattern of pig‐
mented spindle cell nevi with S100A6 protein. J Cutan Pathol. 2011;38(1):14-7.
[228] Slomnicki LP, Nawrot B, Lesniak W. S100A6 binds p53 and affects its activity. Int J
Biochem Cell Biol. 2009;41(4):784-90.
[229] Streicher WW, Lopez MM, Makhatadze GI. Annexin I and annexin II N-terminal
peptides binding to S100 protein family members: specificity and thermodynamic
characterization. Biochemistry. 2009;48(12):2788-98.
[230] Mohan SK, Gupta AA, Yu C. Interaction of the S100A6 mutant (C3S) with the V do‐
main of the receptor for advanced glycation end products (RAGE). Biochem Biophys
Res Commun. 2013;434(2):328-33.
[231] Roth J, Vogl T, Sorg C, Sunderkotter C. Phagocyte-specific S100 proteins: a novel
group of proinflammatory molecules. Trends Immunol. 2003;24(4):155-8.
[232] Yin C, Li H, Zhang B, Liu Y, Lu G, Lu S, et al. RAGE-binding S100A8/A9 promotes
the migration and invasion of human breast cancer cells through actin polymeriza‐
tion and epithelial-mesenchymal transition. Breast Cancer Res Treat. 2013;142(2):
297-309.
[233] Grebhardt S, Muller-Decker K, Bestvater F, Hershfinkel M, Mayer D. Impact of
S100A8/A9 expression on prostate cancer progression in vitro and in vivo. J Cell
Physiol. 2014;229(5):661-71.
[234] Khammanivong A, Wang C, Sorenson BS, Ross KF, Herzberg MC. S100A8/A9 (cal‐
protectin) negatively regulates G2/M cell cycle progression and growth of squamous
cell carcinoma. PLoS One. 2013;8(7):e69395.
[235] Kwon CH, Moon HJ, Park HJ, Choi JH, Park do Y. S100A8 and S100A9 promotes in‐
vasion and migration through p38 mitogen-activated protein kinase-dependent NF-
kappaB activation in gastric cancer cells. Mol Cells. 2013;35(3):226-34.
RAGE and Its Ligands in Melanoma
http://dx.doi.org/10.5772/59172
355
[236] Ehrchen JM, Sunderkotter C, Foell D, Vogl T, Roth J. The endogenous Toll-like recep‐
tor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoim‐
munity, and cancer. J Leukoc Biol. 2009;86(3):557-66.
[237] Ghavami S, Chitayat S, Hashemi M, Eshraghi M, Chazin WJ, Halayko AJ, et al.
S100A8/A9: a Janus-faced molecule in cancer therapy and tumorgenesis. Eur J Phar‐
macol. 2009;625(1-3):73-83.
[238] Ang CW, Nedjadi T, Sheikh AA, Tweedle EM, Tonack S, Honap S, et al. Smad4 loss
is associated with fewer S100A8-positive monocytes in colorectal tumors and attenu‐
ated response to S100A8 in colorectal and pancreatic cancer cells. Carcinogenesis.
2010;31(9):1541-51.
[239] Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G. Proin‐
flammatory S100 proteins regulate the accumulation of myeloid-derived suppressor
cells. J Immunol. 2008;181(7):4666-75.
[240] Srikrishna G. S100A8 and S100A9: new insights into their roles in malignancy. Jour‐
nal of innate immunity. 2012;4(1):31-40.
[241] Wang L, Chang EW, Wong SC, Ong SM, Chong DQ, Ling KL. Increased myeloid-de‐
rived suppressor cells in gastric cancer correlate with cancer stage and plasma
S100A8/A9 proinflammatory proteins. J Immunol. 2013;190(2):794-804.
[242] Basso D, Fogar P, Plebani M. The S100A8/A9 complex reduces CTLA4 expression by
immature myeloid cells: Implications for pancreatic cancer-driven immunosuppres‐
sion. Oncoimmunology. 2013;2(6):e24441.
[243] Burke M, Choksawangkarn W, Edwards N, Ostrand-Rosenberg S, Fenselau C. Exo‐
somes from myeloid-derived suppressor cells carry biologically active proteins. J
Proteome Res. 2014;13(2):836-43.
[244] Petersson S, Shubbar E, Enerback L, Enerback C. Expression patterns of S100 proteins
in melanocytes and melanocytic lesions. Melanoma Res. 2009;19(4):215-25.
[245] Hibino T, Sakaguchi M, Miyamoto S, Yamamoto M, Motoyama A, Hosoi J, et al.
S100A9 is a novel ligand of EMMPRIN that promotes melanoma metastasis. Cancer
Res. 2013;73(1):172-83.
[246] Meyer C, Sevko A, Ramacher M, Bazhin AV, Falk CS, Osen W, et al. Chronic inflam‐
mation promotes myeloid-derived suppressor cell activation blocking antitumor im‐
munity in transgenic mouse melanoma model. Proc Natl Acad Sci U S A.
2011;108(41):17111-6.
[247] Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, et al. MRP8
and MRP14 are endogenous activators of Toll-like receptor 4, promoting lethal, endo‐
toxin-induced shock. Nat Med. 2007;13(9):1042-9.
Melanoma – Current Clinical Management and Future Therapeutics356
[248] Ghavami S, Rashedi I, Dattilo BM, Eshraghi M, Chazin WJ, Hashemi M, et al.
S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and
MAP kinase-dependent pathway. J Leukoc Biol. 2008;83(6):1484-92.
[249] Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J, et al. RAGE, carboxylat‐
ed glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis.
Carcinogenesis. 2008;29:2035-43.
[250] Srikrishna G, Panneerselvam K, Westphal V, Abraham V, Varki A, Freeze HH. Two
proteins modulating transendothelial migration of leukocytes recognize novel car‐
boxylated glycans on endothelial cells. J Immunol. 2001;166(7):4678-88.
[251] Srikrishna G, Nayak J, Weigle B, Temme A, Foell D, Hazelwood L, et al. Carboxylat‐
ed N-glycans on RAGE promote S100A12 binding and signaling. J Cell Biochem.
2010;110(3):645-59.
[252] Hagens G, Masouye I, Augsburger E, Hotz R, Saurat JH, Siegenthaler G. Calcium-
binding protein S100A7 and epidermal-type fatty acid-binding protein are associated
in the cytosol of human keratinocytes. Biochemical Journal. 1999;339:419-27.
[253] Semprini S, Capon F, Tacconelli A, Giardina E, Orecchia A, Mingarelli R, et al. Evi‐
dence for differential S100 gene over-expression in psoriatic patients from genetically
heterogeneous pedigrees. Hum Genet. 2002;111(4-5):310-3.
[254] Brouard MC, Saurat JH, Ghanem G, Siegenthaler G. Urinary excretion of epidermal-
type fatty acid-binding protein and S100A7 protein in patients with cutaneous mela‐
noma. Melanoma Res. 2002;12(6):627-31.
[255] He H, Li J, Weng S, Li M, Yu Y. S100A11: diverse function and pathology corre‐
sponding to different target proteins. Cell Biochem Biophys. 2009;55(3):117-26.
[256] Van Ginkel PR, Gee RL, Walker TM, Hu DN, Heizmann CW, Polans AS. The identifi‐
cation and differential expression of calcium-binding proteins associated with ocular
melanoma. Biochim Biophys Acta. 1998;1448(2):290-7.
[257] Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW. N epsilon-(carboxymeth‐
yl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue pro‐
teins. Biochemistry. 1995;34(34):10872-8.
[258] Thornalley PJ. Advances in glyoxalase research. Glyoxalase expression in malignan‐
cy, anti-proliferative effects of methylglyoxal, glyoxalase I inhibitor diesters and S-D-
lactoylglutathione, and methylglyoxal-modified protein binding and endocytosis by
the advanced glycation endproduct receptor. Crit Rev Oncol Hematol. 1995;20(1-2):
99-128.
[259] Wondrak GT, Jacobson MK, Jacobson EL. Antimelanoma activity of apoptogenic car‐
bonyl scavengers. J Pharmacol Exp Ther. 2006;316(2):805-14.
RAGE and Its Ligands in Melanoma
http://dx.doi.org/10.5772/59172
357
[260] Sander CS, Hamm F, Elsner P, Thiele JJ. Oxidative stress in malignant melanoma and
non-melanoma skin cancer. Br J Dermatol. 2003;148(5):913-22.
[261] Indurthi VS, Leclerc E, Vetter SW. Interaction between glycated serum albumin and
AGE-receptors depends on structural changes and the glycation reagent. Arch Bio‐
chem Biophys. 2012;528(2):185-96.
[262] Bianchi ME, Beltrame M, Paonessa G. Specific recognition of cruciform DNA by nu‐
clear protein HMG1. Science. 1989;243(4894 Pt 1):1056-9.
[263] Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1
as a late mediator of endotoxin lethality in mice. Science. 1999;285(5425):248-51.
[264] Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic
cells triggers inflammation. Nature. 2002;418(6894):191-5.
[265] Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, et al. Toll-like receptor 9-de‐
pendent activation by DNA-containing immune complexes is mediated by HMGB1
and RAGE. Nat Immunol. 2007;8(5):487-96.
[266] Dong Xda E, Ito N, Lotze MT, Demarco RA, Popovic P, Shand SH, et al. High mobili‐
ty group box I (HMGB1) release from tumor cells after treatment: implications for de‐
velopment of targeted chemoimmunotherapy. J Immunother. 2007;30(6):596-606.
[267] Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leu‐
koc Biol. 2007;81(1):1-5.
[268] Tang D, Kang R, Zeh HJ, 3rd, Lotze MT. High-mobility group box 1 and cancer. Bio‐
chim Biophys Acta. 2010;1799(1-2):131-40.
[269] Ito N, DeMarco RA, Mailliard RB, Han J, Rabinowich H, Kalinski P, et al. Cytolytic
cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol. 2007;81(1):
75-83.
[270] Johnson KE, Wulff BC, Oberyszyn TM, Wilgus TA. Ultraviolet light exposure stimu‐
lates HMGB1 release by keratinocytes. Archives of dermatological research.
2013;305(9):805-15.
[271] Bald T, Quast T, Landsberg J, Rogava M, Glodde N, Lopez-Ramos D, et al. Ultravio‐
let-radiation-induced inflammation promotes angiotropism and metastasis in mela‐
noma. Nature. 2014;507(7490):109-13.
[272] Tang Q, Li J, Zhu H, Li P, Zou Z, Xiao Y. Hmgb1-IL-23-IL-17-IL-6-Stat3 axis promotes
tumor growth in murine models of melanoma. Mediators of inflammation.
2013;2013:713859.
[273] Li Q, Li J, Wen T, Zeng W, Peng C, Yan S, et al. Overexpression of HMGB1 in mela‐
noma predicts patient survival and suppression of HMGB1 induces cell cycle arrest
and senescence in association with p21 (Waf1/Cip1) up-regulation via a p53-inde‐
pendent, Sp1-dependent pathway. Oncotarget. 2014;5(15):6387-403.
Melanoma – Current Clinical Management and Future Therapeutics358
[274] O'Connell MP, Weeraratna AT. A spoonful of sugar makes the melanoma go: the role
of heparan sulfate proteoglycans in melanoma metastasis. Pigment Cell Melanoma
Res. 2011;24(6):1133-47.
[275] Nikitovic D, Mytilinaiou M, Berdiaki A, Karamanos NK, Tzanakakis GN. Heparan
sulfate proteoglycans and heparin regulate melanoma cell functions. Biochim Bio‐
phys Acta. 2014;1840(8):2471-81.
[276] Newton RA, Hogg N. The human S100 protein MRP-14 is a novel activator of the be‐
ta 2 integrin Mac-1 on neutrophils. J Immunol. 1998;160(3):1427-35.
[277] Carlos TM. Leukocyte recruitment at sites of tumor: dissonant orchestration. J Leu‐
koc Biol. 2001;70(2):171-84.
[278] Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the im‐
mune system. Nat Rev Immunol. 2009;9(3):162-74.
[279] Mahnke K, Skorokhod A, Grabbe S, Enk AH. Opening a niche for therapy: local lym‐
phodepletion helps the immune system to fight melanoma. J Invest Dermatol.
2014;134(7):1794-6.
[280] Najjar YG, Finke JH. Clinical perspectives on targeting of myeloid derived suppres‐
sor cells in the treatment of cancer. Frontiers in oncology. 2013;3:49.
[281] Riedl S, Rinner B, Asslaber M, Schaider H, Walzer S, Novak A, et al. In search of a
novel target-phosphatidylserine exposed by non-apoptotic tumor cells and metasta‐
ses of malignancies with poor treatment efficacy. Biochim Biophys Acta.
2011;1808(11):2638-45.
[282] Bro S, Flyvbjerg A, Binder CJ, Bang CA, Denner L, Olgaard K, et al. A neutralizing
antibody against receptor for advanced glycation end products (RAGE) reduces athe‐
rosclerosis in uremic mice. Atherosclerosis. 2008;201(2):274-80.
[283] Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, et al. Blockade of RAGE-
amphoterin signalling suppresses tumour growth and metastases. Nature.
2000;405(6784):354-60.
[284] Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, et al. Under‐
standing RAGE, the receptor for advanced glycation end products. J Mol Med.
2005;83(11):876-86.
[285] Hudson BI, Bucciarelli LG, Wendt T, Sakaguchi T, Lalla E, Qu W, et al. Blockade of
receptor for advanced glycation endproducts: a new target for therapeutic interven‐
tion in diabetic complications and inflammatory disorders. Arch Biochem Biophys.
2003;419(1):80-8.
[286] Oldfield MD, Bach LA, Forbes JM, Nikolic-Paterson D, McRobert A, Thallas V, et al.
Advanced glycation end products cause epithelial-myofibroblast transdifferentiation
RAGE and Its Ligands in Melanoma
http://dx.doi.org/10.5772/59172
359
via the receptor for advanced glycation end products (RAGE). J Clin Invest.
2001;108(12):1853-63.
[287] Deane R, Singh I, Sagare AP, Bell RD, Ross NT, LaRue B, et al. A multimodal RAGE-
specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of
Alzheimer disease. J Clin Invest. 2012;122(4):1377-92.
Melanoma – Current Clinical Management and Future Therapeutics360
